Compare DexCom, Inc. (DXCM) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Prologis Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Prologis Inc trades at $128.94 (market cap $122.87B). The key difference: Prologis Inc is far larger — about 3.9× DexCom, Inc.'s market cap, and Prologis Inc pays a 3.31% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Prologis Inc for 102 Days on average.
| DXCM | PLD | |
|---|---|---|
Market Cap | $31.86B | $122.87B |
Volume | 3,607,070 | 4,222,957 |
Sector | Health | Real Estate |
52-Week High | $92.34 | $149.96 |
52-Week Low | $54.84 | $111.23 |
Typical Hold Time | 62 Days | 102 Days |
Enterprise Value | $31.32B | $157.61B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Prologis (PLD) trades at $127.3, down 1.07% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and three consecutive quarterly EPS beats. The stock is supported by robust cash flow from operations of $5.01B in 2025 and positive leasing momentum highlighted by management. Recent news emphasizes growth from warehouse and data center demand, though technical indicators show selling pressure with key support at $126.
The outlook is mixed: analyst consensus is bullish with a $155.15 price target (59.52% buy ratings), but rising debt-to-asset ratios and bearish moving averages pose risks. Upside hinges on continued execution in logistics real estate, while macroeconomic sensitivity and valuation premiums require monitoring for sustained shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
